Travere Therapeutics (TVTX) Stock Price, Quote, News & History

Comments

Travere Therapeutics Inc (TVTX) Stock Price, Quote, News & History

TVTXNASDAQ

Trade with Public

$27.24

-0.07-0.26%

At close: Mar 6, 4:00 PM EST

$27.74

0.501.84%

After Hours: Mar 6, 7:58 PM EST

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$26.61

Close

$27.24

Volume / Avg.

1.43M / 2.12M

Day Range

$26.43 - $27.40

52 Wk Range

12.91 - 42.13

Market Cap

$2.48B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

40

Short Interest

17.13%

Days to Cover

10.77

Recent Travere Therapeutics Inc News

Top 3 Health Care Stocks That Could Blast Off This Month

Avi Kapoor

Travere Stock Slips After FDA Delays Review Of Key Kidney Drug

Travere Therapeutics' stock declines as FDA extends review of key kidney drug. Q4 sales forecast at $127 million.

Vandana Singh

Crude Oil Rises Sharply; US Inflation Rate Holds Steady At 2.7%

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-58.61M

Investing Cash Flow (TTM)

52.42M

Financing Cash Flow (TTM)

78.97M

Free Cash Flow (TTM)

-107.47M

Capital Expenditure (TTM)

-48.85M

Net Change in Cash (TTM)

72.78M

Analyst Trends and Forecast

3

Sep 25

1

Oct 25

1

Nov 25

1

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.75B

PE Ratio (TTM)

-

PE Ratio (FWD)

41.67

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.96

PB Ratio (TTM)

21.92

Earnings Yield % (TTM)

-2.09%

Earnings Yield % (FWD)

2.40%

EV / EBITDA (TTM)

113.57

Price / EBITDA (TTM)

109.58

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.24

Company Debt

Total Debt

$311.37M

LT Debt

$311.37M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$68.90M

Total Cash

$110.93M

Debt to Equity

4.48

Issuance of Debt (TTM)

-$68.90M

Repayment of Debt (TTM)

-$68.90M

Key Statistics

Open

$26.61

Close

$27.24

Volume / Avg.

1.43M / 2.12M

Day Range

$26.43 - $27.40

52 Wk Range

12.91 - 42.13

Market Cap

$2.48B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

40

Short Interest

17.13%

Days to Cover

10.77

About

Sector

Health Care

Industry

Biotechnology

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Travere Therapeutics (TVTX) stock?

A

You can purchase shares of Travere Therapeutics (NASDAQ:TVTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Travere Therapeutics (TVTX) competitors?

A

Other companies in Travere Therapeutics’s space includes: IDEAYA Biosciences Inc (NASDAQ:IDYA), Immunome Inc (NASDAQ:IMNM), Twist Bioscience Corp (NASDAQ:TWST), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) and Ascentage Pharma Group International (NASDAQ:AAPG).

Q

What is the forecast, or price target, for Travere Therapeutics (TVTX) stock?

A

Travere Therapeutics has a consensus price target of $34.56.

Q

What is the current price for Travere Therapeutics (TVTX)?

A

The stock price for Travere Therapeutics (NASDAQ: TVTX) is $27.74 last updated March 6, 2026 at 7:58 PM EST.

Q

Does Travere Therapeutics (TVTX) pay a dividend?

A

There are no upcoming dividends for Travere Therapeutics.

Q

When is Travere Therapeutics (NASDAQ:TVTX) reporting earnings?

A

Travere Therapeutics does not have any upcoming earnings scheduled.

Q

Is Travere Therapeutics (TVTX) going to split?

A

There is no upcoming split for Travere Therapeutics.

Q

What sector and industry does Travere Therapeutics (TVTX) operate in?

A

Travere Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

IDEAYA Biosciences Inc

Twist Bioscience Corp

NASDAQ:TWST

$46.64

-0.63%

Ultragenyx Pharmaceutical Inc

NASDAQ:RARE

$22.00

3.53%

Ascentage Pharma Group International

Arcutis Biotherapeutics Inc

NASDAQ:ARQT

$23.69

-1.29%

Tango Therapeutics Inc

Key Statistics

Open

$26.61

Close

$27.24

Volume / Avg.

1.43M / 2.12M

Day Range

$26.43 - $27.40

52 Wk Range

12.91 - 42.13

Market Cap

$2.48B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

40

Short Interest

17.13%

Days to Cover

10.77

Recent Travere Therapeutics Inc News

Top 3 Health Care Stocks That Could Blast Off This Month

Avi Kapoor

Travere Stock Slips After FDA Delays Review Of Key Kidney Drug

Travere Therapeutics' stock declines as FDA extends review of key kidney drug. Q4 sales forecast at $127 million.

Vandana Singh

Crude Oil Rises Sharply; US Inflation Rate Holds Steady At 2.7%

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-58.61M

Investing Cash Flow (TTM)

52.42M

Financing Cash Flow (TTM)

78.97M

Free Cash Flow (TTM)

-107.47M

Capital Expenditure (TTM)

-48.85M

Net Change in Cash (TTM)

72.78M

Analyst Trends and Forecast

3

Sep 25

1

Oct 25

1

Nov 25

1

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.75B

PE Ratio (TTM)

-

PE Ratio (FWD)

41.67

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.96

PB Ratio (TTM)

21.92

Earnings Yield % (TTM)

-2.09%

Earnings Yield % (FWD)

2.40%

EV / EBITDA (TTM)

113.57

Price / EBITDA (TTM)

109.58

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.24

Company Debt

Total Debt

$311.37M

LT Debt

$311.37M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$68.90M

Total Cash

$110.93M

Debt to Equity

4.48

Issuance of Debt (TTM)

-$68.90M

Repayment of Debt (TTM)

-$68.90M

Key Statistics

Open

$26.61

Close

$27.24

Volume / Avg.

1.43M / 2.12M

Day Range

$26.43 - $27.40

52 Wk Range

12.91 - 42.13

Market Cap

$2.48B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

40

Short Interest

17.13%

Days to Cover

10.77

About

Sector

Health Care

Industry

Biotechnology

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry